Skip to main content
. 2018 Jul 26;6(4):429–449. doi: 10.1016/j.jcmgh.2018.07.003

Figure 5.

Figure 5

Col6a1 is controlled by the Rarb/Runx3 signal axis. (A) Quantitative RT-PCR (left panel) and Western blot (right panel) analysis show expression of Runx3; H, hyperglycemic cells; L, hypoglycemic cells. (B) Quantitative RT-PCR analysis shows expression of Runx1 and Runx2 in hyperglycemic and hypoglycemic PDAC cells. (C) Western blot analysis shows expression of Runx/Col6a1 in another (634 cells) hyperglycemic (H) and hypoglycemic (L) PDAC cells. (D) Western blot analysis shows expression of Smad4 and p53 in hyperglycemic (H) and hypoglycemic (L) PDAC cells. (E) Quantitative RT-PCR analysis shows expression of Rarb (left panel) and its target gene Egr2 (right panel) in hyperglycemic and hypoglycemic cells. (F) Real-time PCR analysis shows expression of Rarg and Rara in hyperglycemic (H) and hypoglycemic (L) PDAC cells. (G) Mass spectrometry analysis shows intracellular levels of RA in hyperglycemic and hypoglycemic PDAC cells. (H) Quantitative PCR analysis shows expression of Rarb, Runx3, and Col6a1 after Rar inhibition (by pan-Rar antagonist AGN193109, 50 μmol/L) for 24 hours. (I) Western blot analysis shows expression of Rarb, Runx3, and Col6a1 after Rar inhibition in hyperglycemic PDAC cells. All data are presented as mean ± standard deviation, and data from 3 independent experiments are shown. Unpaired t test is applied, *P < .05.